
PHARMAXIS INVESTOR CONFERENCE CALL – BRONCHITOL EU RE-EXAMINATION

Pharmaxis Ltd (PXS) expects to receive definitive notification of the outcome of the re-examination of Bronchitol® for the treatment of cystic fibrosis from the European Committee for Medicinal Products for Human Use on the evening of Friday 21 October 2011 (Australian time). The Company therefore anticipates making an announcement concerning the re-examination by 8.30am Monday 24 October 2011. That announcement will have the effect of ending the current voluntary suspension of the Company's shares.

The Company will hold an investor teleconference at 9.00am Monday 24 October to discuss the announcement.

Telephone access (toll free):

- Australia: 1800 558 698
- USA/Canada: 1877 642 9125
- UK: 0800 635 0664
- NZ: 0800 446 958

Telephone access (metered): +61 7 3107 0210

Online access details are available on the Pharmaxis website home page at:
www.pharmaxis.com.au

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Pharmaxis Investor Relations

T: +61 2 9454 7200, F: +61 2 9451 3622,

E: Investor.Relations@Pharmaxis.com.au Website: www.pharmaxis.com.au